menu

ReachMD

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

An Individualized Approach to Optimize Obesity Treatment

The treatment landscape of obesity pharmacotherapy has also evolved rapidly in recent years. These developments underscore the need for clinicians ...

Available credits: 0.25

Time to complete: 15 Minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The treatment landscape of obesity pharmacotherapy has also evolved rapidly in recent years. These developments underscore the need for clinicians to be familiar with the various therapeutic options in order to the best possible treatment for individual patients. This CME activity will cover the safety and efficacy of pharmacologic therapy for obesity, the different mechanisms of action of these agents, and the factors to consider when selecting treatment. 

  • Disclosure of Conflicts of Interest

    The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

    The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

    The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

    Caroline M. Apovian, MD, FTOS:
    Consulting Fee: Abbott, Amylin, Arena, Aventis, Johnson & Johnson,
    Medscape, Merck, Myos Corporation, Novo Nordisk, Inc., Nutrisystem,
    Orexigen, Pfi zer, Sanofi , Scientifi c Intake, Zafgen
    Speakers Bureau: Qysmia, Takeda Pharmaceuticals
    Contracted Research: Amylin, Aspire Bariatrics, GI Dynamics, Orexigen,
    Takeda Pharmaceuticals

    Louis J. Aronne, MD, FTOS:
    Consulting Fee: Arena, Eisai, Ethicon Endo-Surgery, Gelesis, GI Dynamics,
    Jamieson Labs, JOVIA Health, Novo Nordisk, Pfi zer,
    Takeda Pharmaceuticals, Vivus, Zafgen
    Contracted Research: Aspire Bariatrics, Eisai, GI Dynamics, Novo Nordisk
    Ownership Interest: BMIQ, Gelesis, Jamieson Labs, Myos Corporation, Zafgen
    Board of Directors: Myos Corporation, Jamieson

    The following SPC member who planned and/or reviewed content for this activity reported no relevant financial relationships:

    Connie Newman, MD
    Endocrine Society and Vindico Medical Education staff associated with the development of content for this activity reported no relevant financial relationships. Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

  • Target Audience

    The intended audience for the activity is primary care physicians and other health care professionals involved in the treatment of patients with obesity.

  • Learning Objectives

    An Individualized Approach to Optimize Obesity Treatment

    • Assess pharmacologic options for their safety and efficacy and how they can be used in individual patients with obesity.
  • Accreditation and Credit Designation Statements

    The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation. 

    The Endocrine Society designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

          

  • Commercial Support

    This activity is supported by an educational grant from Novo Nordisk, Inc.

  • Terms of Use

    The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

  • Instructions

    To participate in this CME activity, you must read the objectives, answer the pretest question, view content, complete the CME posttest, and complete and return the registration form and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 67% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate for immediate download on www.reachmd.com.

  • Disclaimer

    Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2016 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of The Endocrine Society and Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of The Endocrine Society and Vindico Medical Education. Neither The Endocrine Society, Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

    CME Questions?
    Contact us at cme@vindicoCME.com

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience."

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.